Abstract: A vehicle crash cushion for decelerating a vehicle includes first, second and third bays. The first bay is positioned forwardly of the second bay and the second bay is positioned forwardly of the third bay. The first, second and third bays each have energy absorbing structures with first, second and third impact strengths respectively. The first impact strength is greater than the third impact strength, which is greater than the second impact strength. In another aspect, a deformable tube is at least partially filled with a secondary component, which filled portion has a greater deformation strength than unfilled portions of the tube. In another aspect, a vehicle crash cushion includes first and second side panels. A connector includes a first strap portion disposed in a valley of and connected to the first side panel and a second strap portion disposed adjacent to and connected to a ridge of the second side panel.

Abstract: A vehicle crash cushion for decelerating a vehicle includes front and rear anchors spaced along a longitudinal direction and at least one deformable attenuator member extending in the longitudinal direction and having a first end coupled to the front anchor and a second end coupled to the rear anchor. A support member is positioned adjacent the attenuator member and is moveable in the longitudinal direction relative thereto between at least an initial position and an impact position toward the rear anchor and away from the front anchor. At least one deforming member is mounted on the support member and is engaged with at least a portion of the attenuator member. In another aspect, a vehicle crash cushion includes first and second side panels each having at least one longitudinally extending ridge and at least one longitudinally extending valley. The first side panel is moveable relative to the second side panel in response to an axial force being applied to the elongated frame.

Abstract: Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, and of such other enumerated conditions as can be treated with inhibitors of DPP IV.

Abstract: The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.

Abstract: The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.

Abstract: The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.